News

Yankees Legend Bernie Williams Raises Awareness of IPF to Honor His Dad

New York Yankees legend Bernie Williams is collaborating with Boehringer Ingelheim to raise awareness of idiopathic pulmonary fibrosis (IPF), a disease that took the life of his father, Barnabé Williams, in 2001. Williams will participate in the Sin Aliento campaign on Father’s Day, June 18, to encourage those who may have IPF to…

Lung Therapy Developer Pulmatrix Licenses RespiVert’s Kinase Inhibitor Compounds

Pulmatrix, which develops inhaled therapies for lung diseases, has licensed the kinase inhibitor compounds that RespiVert has created to inhibit enzymes involved in inflammation. “These new compounds will significantly expand what we believe is already an impressive pipeline of [Pulmatrix’s] drug candidates,” Dr. Robert Clarke, Pulmatrix’s CEO, said in a…

PETA Donates Systems for Animal-free Inhalation Tests to Centers in US and Europe

An arm of People for the Ethical Treatment of Animals (PETA) is donating equipment that allows for animal-free testing of the effects of inhaled particles on the lungs to select laboratories across the United States and Europe. Valued at more than $400,000, the Vitrocell Systems inhalation device exposes human lung cells to tested materials…

Surgery to Prevent Reflux in IPF Patients May Be Superior to Anti-Acid Medicines, Study Says

Surgery to prevent reflux in patients with interstitial pulmonary disease may slow disease progression, by stopping tiny amounts of contents in the stomach from being repeatedly aspirated into the lungs — a process thought to contribute to disease development in IPF. This was the conclusion of a review looking into gastroesophageal reflux disease —…

Lung Therapeutics Raises $14.3 Million to Develop Treatments for Pulmonary Fibrosis, Other Diseases

Lung Therapeutics announced June 6 that it has completed a $14.3 million Series B financing round to support development of LTI-03, its lead therapy for idiopathic pulmonary fibrosis (IPF). LTI-03 has already showed promising results for other conditions including scleroderma and cardiac fibrosis. The funds will also support clinical trials, now underway in Australia and…